Global Neuroendocrine Tumors Market Size To Exceed USD 10.35 Billion By 2035 | CAGR of 10.30%
Category: HealthcareGlobal Neuroendocrine Tumors Market Size To Exceed USD 10.35 Billion By 2035
According to a research report published by Spherical Insights & Consulting, the Global Neuroendocrine Tumors Market Size is Expected to Grow from USD 3.52 Billion in 2024 to USD 10.35 Billion by 2035, at a CAGR of 10.30% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 210 pages with 130 Market data tables and figures & charts from the report on the "Global Neuroendocrine Tumors Market Size, Share, and COVID-19 Impact Analysis, By Product (Somatostatin Analogs, Targeted Therapy, and Chemotherapy), By End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035."Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/neuroendocrine-tumors-market
The market for neuroendocrine tumors (NETs) is expanding as a result of improvements in diagnosis and therapy. Rare malignancies known as NETs develop from neuroendocrine cells and impair organs such as the gastrointestinal tract, lungs, and pancreas. Pharmaceuticals, imaging technology, and treatments like immunotherapy, targeted therapies, and somatostatin analogs are all part of the neuroendocrine tumors market. Growth is being propelled by improved healthcare facilities, more awareness, and financing for research. Personalized medicine strategies that are tailored to the specific characteristics of each tumor are also driving the neuroendocrine tumors market. The primary forces behind the market's growth are the rising prevalence of neuroendocrine tumors and significant advancements in diagnostic techniques that allow for earlier and more accurate detection. Due to the complexity and diversity of NETs, specialist neuroendocrine tumor centers are emerging, and interdisciplinary team approaches are becoming more popular. However, high treatment costs, little awareness, delayed diagnosis, stringent regulations, and insufficient access to expert care are some of the challenges facing the neuroendocrine tumors (NETs) market.
The somatostatin analogs segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the product, the neuroendocrine tumors market is divided into somatostatin analogs, targeted therapy, and chemotherapy. Among these, the somatostatin analogs segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The somatostatin analogs are effective in both symptom management and tumor development inhibition in a significant number of somatostatin receptor-positive NETs, they are positioned as a first-line and long-term therapeutic option.
The hospitals segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the end user, the neuroendocrine tumors market is divided into hospitals, specialty clinics, radiation centers, home healthcare, and others. Among these, the hospitals segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The hospitals' extensive infrastructure, availability of interdisciplinary teams, sophisticated diagnostic capabilities, and ability to perform intricate, frequently inpatient procedures like PRRT and specialist operations are factors propel the hospitals segment.
North America is expected to hold the majority share of the global neuroendocrine tumors market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global neuroendocrine tumors market during the forecast period. The improvement of NET management through accurate diagnosis instruments and efficient treatment plans is becoming a higher priority for healthcare providers. The market is growing as a result of the growing integration of clinical research and development, which is backed by substantial government funding and pharmaceutical expenditures.
Asia Pacific is anticipated to grow at the fastest pace in the global neuroendocrine tumors market during the forecast period. India's neuroendocrine tumor market has the largest revenue share in Asia Pacific due to factors such rapid urbanization, the expansion of the middle class, and easier access to specialized medical facilities.
Major vendors in the global neuroendocrine tumors market are Lupin, Lilly, HUTCHMED, GSK plc, Pfizer Inc., BioSynthema Inc., Exact Sciences Corporation, Ipsen Pharma, Bionano Genomics, Inc., Illumina, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Advanced Accelerator Applications SA, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In March 2024, Paltusotine is an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome. Today, the clinical stage pharmaceutical company (Nasdaq: CRNX), which focuses on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced positive topline results from its open-label Phase 2 carcinoid syndrome study.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the neuroendocrine tumors market based on the below-mentioned segments:
Global Neuroendocrine Tumors Market, By Product
- Somatostatin Analogs
- Targeted Therapy
- Chemotherapy
Global Neuroendocrine Tumors Market, By End User
- Hospitals
- Specialty Clinics
- Radiation Centers
- Home Healthcare
- Others
Global Neuroendocrine Tumors Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?